Biosure: against COVID-19 Company
Entity: Biosure
Category: Test Kits
Description: At BioSure they specialise in providing solutions. They develop, manufacture, source and distribute world class point of care rapid tests. They understand the importance of ease of use where immediate results are the primary consideration, their tests provide the highest levels of accuracy, rivalling those of standard laboratory tests. Since launching the world's first apporved HIV self test to use blood, they have become experts in this field and have unique and unrivalled knowledge of the global landscape. They passionately believe that this technology through can revolutionise testing protocols, reduce late diagnoses, provide cost effective testing solutions and engage hard to reach key populations. Ultimately budgets can be spread further through far lower delivery costs and immediate diagnosis.
Project: Mologic + BioSure Coronavirus $1 Rapid Test
Summary: By combining Mologic’s independently verified COVID-19 lateral flow test with BioSure’s market-leading design, the companies have created a self-test for COVID-19 that can be used without any training being required. The innovative design has been proven to be extremely easy to use, requires only a fraction of a drop of blood and gives the user their own result in just 10 minutes. Since launching the first CE marked HIV self-test in 2015, BioSure have become world-leading experts in self-testing.
+ Investors:
Pitch@Palace
VentureFounders
Category: Test Kits
Description: At BioSure they specialise in providing solutions. They develop, manufacture, source and distribute world class point of care rapid tests. They understand the importance of ease of use where immediate results are the primary consideration, their tests provide the highest levels of accuracy, rivalling those of standard laboratory tests. Since launching the world's first apporved HIV self test to use blood, they have become experts in this field and have unique and unrivalled knowledge of the global landscape. They passionately believe that this technology through can revolutionise testing protocols, reduce late diagnoses, provide cost effective testing solutions and engage hard to reach key populations. Ultimately budgets can be spread further through far lower delivery costs and immediate diagnosis.
Project: Mologic + BioSure Coronavirus $1 Rapid Test
Summary: By combining Mologic’s independently verified COVID-19 lateral flow test with BioSure’s market-leading design, the companies have created a self-test for COVID-19 that can be used without any training being required. The innovative design has been proven to be extremely easy to use, requires only a fraction of a drop of blood and gives the user their own result in just 10 minutes. Since launching the first CE marked HIV self-test in 2015, BioSure have become world-leading experts in self-testing.
+ Investors:
Pitch@Palace
VentureFounders
Technology:
Test Kits
Headquarters:
United Kingdom
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership